Pharming Group NV (PHAR) - Total Liabilities
Based on the latest financial reports, Pharming Group NV (PHAR) has total liabilities worth $178.15 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pharming Group NV cash flow conversion to assess how effectively this company generates cash.
Pharming Group NV - Total Liabilities Trend (2005–2024)
This chart illustrates how Pharming Group NV's total liabilities have evolved over time, based on quarterly financial data. Check PHAR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Pharming Group NV Competitors by Total Liabilities
The table below lists competitors of Pharming Group NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
China | CN¥1.77 Billion |
|
Perpetual Limited
F:PVQ
|
Germany | €1.77 Billion |
|
thyssenkrupp nucera AG & Co. KGaA
XETRA:NCH2
|
Germany | €384.00 Million |
|
Cadre Holdings Inc
NYSE:CDRE
|
USA | $452.23 Million |
|
Darma Henwa Tbk
JK:DEWA
|
Indonesia | Rp5.16 Trillion |
|
Aavas Financiers Limited
NSE:AAVAS
|
India | Rs147.61 Billion |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
USA | $153.92K |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
Indonesia | Rp14.63 Trillion |
Liability Composition Analysis (2005–2024)
This chart breaks down Pharming Group NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PHAR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharming Group NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharming Group NV (2005–2024)
The table below shows the annual total liabilities of Pharming Group NV from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $178.92 Million | -26.69% |
| 2023-12-31 | $244.07 Million | +10.36% |
| 2022-12-31 | $221.16 Million | +8.20% |
| 2021-12-31 | $204.40 Million | +6.24% |
| 2020-12-31 | $192.39 Million | +38.88% |
| 2019-12-31 | $138.53 Million | -20.76% |
| 2018-12-31 | $174.81 Million | -1.14% |
| 2017-12-31 | $176.82 Million | +69.29% |
| 2016-12-31 | $104.45 Million | +182.34% |
| 2015-12-31 | $37.00 Million | +17.58% |
| 2014-12-31 | $31.46 Million | -13.68% |
| 2013-12-31 | $36.45 Million | +12.52% |
| 2012-12-31 | $32.40 Million | -3.43% |
| 2011-12-31 | $33.55 Million | -7.23% |
| 2010-12-31 | $36.16 Million | -40.72% |
| 2009-12-31 | $60.99 Million | -19.70% |
| 2008-12-31 | $75.96 Million | -34.60% |
| 2007-12-31 | $116.14 Million | +200.99% |
| 2006-12-31 | $38.59 Million | +457.08% |
| 2005-12-31 | $6.93 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more